Screener
Axsome Therapeutics AXSM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
| Net loss | $(64,542) | $(59,413) |
| Net loss per common share, basic and diluted | $(1.26) | $(1.22) |
| Weighted average common shares outstanding, basic and diluted | 51,198,349 | 48,871,163 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's net income?
- Axsome Therapeutics (AXSM) reported net income of -$64.54M in Q1 2026.
- How has Axsome Therapeutics's net income changed year-over-year?
- Axsome Therapeutics's net income decreased by 8.6% year-over-year, from -$59.41M to -$64.54M.
- What is the long-term trend for Axsome Therapeutics's net income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's net income has grown at a 8.9% compound annual growth rate (CAGR), from -$130.4M to -$183.17M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Axsome Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude